What is William Blair’s Forecast for VKTX FY2027 Earnings?

Viking Therapeutics, Inc. (NASDAQ:VKTX) – Stock analysts at William Blair issued their FY2027 EPS estimates for Viking Therapeutics in a note issued to investors on Wednesday, February 5th. William Blair analyst A. Hsieh forecasts that the biotechnology company will post earnings per share of ($2.42) for the year. William Blair has a “Outperform” rating on the stock. The consensus estimate for Viking Therapeutics’ current full-year earnings is ($0.97) per share.

Viking Therapeutics (NASDAQ:VKTX) last announced its earnings results on Wednesday, February 5th. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.05). During the same quarter in the previous year, the firm posted ($0.25) earnings per share.

VKTX has been the topic of a number of other reports. StockNews.com raised shares of Viking Therapeutics to a “sell” rating in a research note on Tuesday, October 15th. HC Wainwright restated a “buy” rating and issued a $102.00 target price on shares of Viking Therapeutics in a research report on Thursday. B. Riley initiated coverage on Viking Therapeutics in a research report on Friday, November 22nd. They set a “buy” rating and a $109.00 price target for the company. Raymond James raised their price objective on Viking Therapeutics from $122.00 to $125.00 and gave the company a “strong-buy” rating in a report on Thursday. Finally, Piper Sandler dropped their target price on shares of Viking Therapeutics from $74.00 to $71.00 and set an “overweight” rating for the company in a report on Thursday. One analyst has rated the stock with a sell rating, eleven have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $107.08.

Viking Therapeutics Stock Down 6.1 %

VKTX opened at $31.46 on Friday. The firm’s fifty day simple moving average is $40.46 and its two-hundred day simple moving average is $54.01. Viking Therapeutics has a 52-week low of $23.81 and a 52-week high of $99.41. The company has a market cap of $3.51 billion, a price-to-earnings ratio of -33.83 and a beta of 0.90.

Institutional Trading of Viking Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in VKTX. Blue Trust Inc. acquired a new stake in shares of Viking Therapeutics in the third quarter valued at $26,000. GAMMA Investing LLC lifted its stake in Viking Therapeutics by 124.6% during the 3rd quarter. GAMMA Investing LLC now owns 438 shares of the biotechnology company’s stock worth $28,000 after acquiring an additional 243 shares in the last quarter. Gilliland Jeter Wealth Management LLC purchased a new position in Viking Therapeutics during the 3rd quarter valued at about $32,000. Stone House Investment Management LLC grew its position in Viking Therapeutics by 66.7% in the 3rd quarter. Stone House Investment Management LLC now owns 500 shares of the biotechnology company’s stock valued at $32,000 after acquiring an additional 200 shares in the last quarter. Finally, YANKCOM Partnership purchased a new stake in Viking Therapeutics during the fourth quarter worth about $33,000. Hedge funds and other institutional investors own 76.03% of the company’s stock.

Insider Transactions at Viking Therapeutics

In other news, CEO Brian Lian sold 194,490 shares of the business’s stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $42.75, for a total value of $8,314,447.50. Following the sale, the chief executive officer now directly owns 2,366,570 shares of the company’s stock, valued at approximately $101,170,867.50. The trade was a 7.59 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Marianna Mancini sold 54,215 shares of the stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $42.75, for a total transaction of $2,317,691.25. Following the transaction, the chief operating officer now directly owns 374,134 shares of the company’s stock, valued at $15,994,228.50. The trade was a 12.66 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 299,014 shares of company stock worth $12,782,849. 4.70% of the stock is currently owned by company insiders.

About Viking Therapeutics

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.